Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI

Affinity Asset Advisors LLC lifted its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 102.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,534,058 shares of the company’s stock after purchasing an additional 1,284,058 shares during the quarter. Trevi Therapeutics accounts for about 1.9% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 15th biggest holding. Affinity Asset Advisors LLC owned 2.08% of Trevi Therapeutics worth $13,861,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Russell Investments Group Ltd. boosted its position in shares of Trevi Therapeutics by 194.5% during the second quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after buying an additional 2,996 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Trevi Therapeutics by 15,969.1% in the second quarter. Farther Finance Advisors LLC now owns 8,838 shares of the company’s stock worth $48,000 after purchasing an additional 8,783 shares during the last quarter. Strs Ohio purchased a new position in shares of Trevi Therapeutics in the 1st quarter worth $52,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Trevi Therapeutics in the second quarter worth $56,000. Finally, Steward Partners Investment Advisory LLC grew its stake in shares of Trevi Therapeutics by 20.0% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 12,000 shares of the company’s stock valued at $66,000 after purchasing an additional 2,000 shares during the period. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Stock Performance

TRVI opened at $13.47 on Friday. The firm has a market cap of $1.73 billion, a P/E ratio of -36.40 and a beta of 0.83. The stock has a 50-day moving average of $11.07 and a 200 day moving average of $8.43. Trevi Therapeutics, Inc. has a 12 month low of $2.36 and a 12 month high of $14.00.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.02. On average, research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on TRVI shares. Oppenheimer lifted their price target on shares of Trevi Therapeutics from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Needham & Company LLC lowered their price objective on Trevi Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, August 8th. Raymond James Financial decreased their target price on shares of Trevi Therapeutics from $29.00 to $27.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Wednesday, October 8th. Finally, Morgan Stanley raised their price objective on shares of Trevi Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $21.44.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.